로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > LRRK2

LRRK2

요약

Name:Leucine-rich repeat serine/threonine-protein kinase 2
Target Synonym:PARK8,LRRK2,Leucine Rich Repeat Kinase 2,Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2,Parkinson Disease (Autosomal Dominant) 8,Augmented In Rheumatoid Arthritis 17,Dardarin,AURA17,RIPK7,ROCO2,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2,DKFZp434H2111,FLJ45829
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

제품 리스트 비교 또는 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
LK2-H5243 Human Human LRRK2 Protein, His Tag
LK2-H5243-structure
LK2-H5245 Human Human LRRK2 (G2019S) Protein, His Tag
LK2-H5245-structure

Synonym Name

PARK8,Leu-rich repeat/LRR-containing protein kinase 2,Dardarin

Background

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin and PARK8, is a kinase enzyme that in humans is encoded by the LRRK2 gene. LRRK2 is a member of the leucine-rich repeat kinase family, which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, autophagy, and vesicle trafficking. Mutations in the LRRK2 gene causes one of the most common monogenic forms of Parkinson disease (PD) . Also, several polymorphic variants in LRRK2 also modulate risk of sporadic PD.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
VRN-01 VRN-01 Phase 1 Clinical Voronoi Pancreatic Neoplasms; Breast Neoplasms Details
DNL-201 DNL-201 F. Hoffmann-La Roche Ltd Details
BIIB-094 BIIB-094; ION-859; IONIS-BIIB7Rx Phase 2 Clinical Biogen Inc Parkinson Disease Details
DNL-151 BIIB-122; DNL-151 Phase 3 Clinical Biogen Inc, F. Hoffmann-La Roche Ltd Parkinson Disease Details
WXWH0226 WXWH0226; WXWH-0226 Phase 1 Clinical Guizhou Inochini Technology Co Ltd Parkinson Disease Details

This web search service is supported by Google Inc.

totop